Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDC 1421

Next Previous
Drug Profile

PDC 1421

Alternative Names: ABV 1504; ABV 1505; ABV-1601; BLI-1005; PDC-1421

Latest Information Update: 22 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical and Pharmaceutical Industry Technology and Development Center
  • Developer ABVC BioPharma; BioLite Inc; Cedars-Sinai Medical Center; Stanford University; Taipei Veterans General Hospital; University of California at San Francisco
  • Class Antidepressants; Behavioural disorder therapies; Traditional Chinese medicine
  • Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder; Major depressive disorder
  • Preclinical Neurological disorders

Most Recent Events

  • 14 Nov 2024 ABVC BioPharma anticipates an US FDA End-of-Phase II meeting to finalize the phase III trial protocol
  • 14 Nov 2024 ABVC Biopharma plans a phase I trial for Major depressive disorder by the end of 2024
  • 09 Aug 2024 BioLite completes a phase II trial in Attention-deficit hyperactivity disorder in USA (PO) (NCT05202327)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top